Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.14 | N/A | +7.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.14 | N/A | +7.34% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about future growth driven by new product pipelines. They emphasized the need for continued innovation.
Management highlighted ongoing investments in R&D as a priority.
They noted the importance of maintaining market share in a competitive landscape.
Eli Lilly's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.9% in reaction, likely due to the lack of revenue details and forward guidance. Investors may be concerned about the company's future performance without clearer direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 22, 2013